Page 114 - 2020_01-Haematologica-web

M. Stahl et al.
Table 1. ATG.
Author Year
Molldrem JJ et al. 2002
Steensma DP et al. 2003 Killick S. et al. 2003
Stadler et al. 2004
Komrokji R. et al. 2014
Yazji S. et al. 2003
Saunthararajah Y et al. 2003
Treatment and treatment schedule
ATG 40mg/kg/d for 4 doses
r-ATG 40mg/kg/d for 4 doses
Lymphoglobuline 15mg/kg/d for 5 doses
r-ATG 3.75 mg/kg/d h-ATG:
15 mg/kg/d for 5 doses
r-ATG 10mg/kg/d for 4 doses
ATG 40mg/d for 4 doses
N
61
8
30
35
27
IPSS
risk category
Low: 18% Intermediate-1: 67% Intermediate 2: 5% High: 10%
Intermediate-1: 63%
Intermediate-2: 37% Not reported
Low: 14%
Intermediate-1: 57% Intermediate-2: 26% High: 3%
Low: 30% Intermediate-1: 56% Intermediate 2: 14%
Not reported
Not reported
Low: 72%
Intermediate-1: 28% Not reported
FAB/WHO classification
RA: 61% RARS: 16% RAEB: 23%
RA: 25%
RAEB-I: 75% RA: 43% RARS: 10% RCMD: 33% RAEB-I: 14% RA: 37% RCMD: 37% CMML: 3% RAEB-I: 17% RAEB-II: 11% RA: 7% RCMD: 30% MDS-U: 19% MDS/MPN: 4% RAEB: 19% RA/RARS: 58% CMML: 3% RAEB-I/II: 39%
RA: 74% RARS: 9% RAEB-I/II: 17% RA: 80% RAEB-I: 20% Not reported PR: 20%
RA: 4%
RCMD: 92%
MDS-U: 4%
RA: 47%
RARS: 13%
RAEB-I: 20% Hypoplastic MDS: 20%
+ CsA titrated to 200-400mg/dl
for 6 months + methylprednisolone 1mg/kg for 4 days followed
by oral taper over 1 month 31
Outcomes
NoCRsorPR HI-E: 34%
TI: 34%
No responses
CR: 5% PR: 45% HI-E: 45%
CR: 11%
PR: 17% HI-E: 26% TI: 20%
NoCRorPR HI-E: 39%
CR: 13%
PR: 3% TI: 19%
HI-E: 30% TI: 30%
CR: 15%
PR: 15% CR: 7%
CR: 16%
HI-E: 77%
Adverse Ref. events
Every patient (28) with serum
sickness; no
CTCAE
grading provided
20 AE, no CTCAE (33)
grading provided
46 AE, no grading (34) provided
AE ≥ grade 3: 66% (35)
70 AE (16) 9AE≥grade3
(4 infectious)
65AEin (30)
31 patients; 7AEs≥grade3 (0 infectious)
Not reported (21)
6 patients off trial (36)
due to AE
79AEin15 (37) patients of which
35 AE ≥grade 3
(6 infectious)
Not reported (13)
16 patients with (18) SAE (4 infectious)
Not reported (17)
for MDS cohort independently
ATG 40mg/kg/d for 4 doses + CsA 5-12mg/kg/d for 6 months
23
25
Broliden PA et al
Garg R. et al.
Xiao, L et al.
Passweg JR et al.
Kadia TM et al.
2006 ATG 10-20mg/kg/d for 3 doses;
CsA 200ng/ml for 32 weeks 2009 rATG 3.5 mg/kg/d for 5 doses
15
+ Methylprednisolone 1 mg/kg/day IV for 5 doses with PO prednisone taper
over 3 weeks + CsA 5 mg/kg/d ≥6 months for trough of 200 and 400 mg/dl + G-CSF 5
μg/kg/d s.c. daily for 3 months 2012 CsA 3-5mg/kg/d for 6 months 71
+/- ATG 4mg/kg/d for 4 doses
2011 h-ATG 15mg/kg/d for 5 doses 45 + CsA for 6 months
2012 ATG (3.5 mg/kg/day × 5 days 24
+ CsA 5 mg/kg/d × 6 months
+ methylprednisolone 1 mg/kg/d
with 1month taper of prednisone
Low: 100%
Low: 18% Intermediate-I: 53% Intermediate-II: 16% High: 2%
Not reported
TI: 64% CR: 7% PR: 24%
Not reported
CR: 8%
HI-E: 17% TI: 8%
continued on the next page
104
haematologica | 2020; 105(1)